Advisors & Consultants


Louis Harris, PH.D., Consultant, Animal Behavior / Drug Evaluation & Development

Dr. Harris is a Professor at the Medical College of Virginia / Virginia Commonwealth University and is a pre-eminent researcher in the testing of behavioral effects of psychoactive drugs in animal models. He is a founding and leading member of the Committee on Problems of Drug Dependence (CPDD) for the National Institute on Drug Abuse (NIDA).  He is also a member of the Drug Evaluation Committee (DEC), a CPDD subgroup that tests and approves candidate drugs for further clinical trials testing. With CPDD, Harris has amassed considerable experience with hundreds of analgesic (esp. opioid) candidate drugs in development over the past 30 years.  Dr. Harris avidly supports the continued animal and human testing of PPL's compounds.

 

 

Mary Jeanne Kreek, M.D., Consultant, Addictive Diseases and Therapy

Dr. Kreek is Senior Attending Physician and Patrick E. and Beatrice M. Haggerty Professor, Head of Laboratory of Biology of Addictive Diseases, The Rockefeller University. She is the recipient of numerous professional awards including:  Betty Ford Award, Association for Medical Education and Research in Substance Abuse, 1996; Specific Recognition Award, Research in Science of Addiction, Executive Office of the President – Office of National Drug Control Policy 1998; R. Brinkley Smithers Distinguished Scientist Award, American Society of Addiction Medicine, 1999; Nathan B. Eddy Memorial Award for Life-time Excellence in Drug Abuse Research, College on Problems of Drug Dependence, 1999; Fellow, New York Academy of Sciences, 2000; Columbia University College of Physicians and Surgeons Alumni Association – Gold Medal for Distinguished Achievements in Academic Medicine, 2004; Marian W. Fischman Memorial Lectureship Award, College on Problems of Drug Dependence, 2005; President, International Narcotics Research Conference 2002-2006. Dr Kreek holds a BA in Chenistry from Wellesley College and an MD from Columbia College of Physicians and Surgeons, Sigma Xi, Phi Beta Kappa: Durant Scholar.

 

 

Shayne Gad, Ph.D., Consultant, Toxicology and Regulatory Affairs

Dr. Gad is Principal, Gad Consulting Services, a twenty year old consulting firm with over 300 pharmaceutical companies as clients. He has more than 35 years of broad-based experience in toxicology, drug development, statistics and risk assessment and has authored or edited 44 published books in these fields. He is the recipient of the American College of Toxicology Lifetime Contribution Award. He has direct involvement in the preparation of INDs (96 successful to date), NDA, PLA, ANDA, 510(k), IDE, CTD, clinical data bases for Phase I and II studies, and PMAs. He has consulted for FDA, EPA AND NIH, and has trained reviewers and been an expert witness for the FDA. Shayne holds two BS degrees from Whittier College in Chemistry and Biology, and a Ph.D. in Pharmacology / Toxicology from the University of Texas DABT, ATS.

 

 

John Mendelson, M.D., Consultant, Clinical Trial Design

Dr. Mendelson is Senior Scientist, Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute and is also Clinical Professor of Medicine at the University of California, San Francisco. He is also a member of the FDA Analgesic Drugs Advisory Committee. He is the former Chair of the California Pacific Medical Center Institutional Review Board. He is Selected, Best Doctors USA and has frequently served as Section Chair of the American Society of Clinical Pharmacology and Therapeutics. He has specific expertise in the design and supervision of human clinical trials of controlled substances. John holds a BA in Biology from Antioch College and an MD from the University of California, San Francisco.

 

 

Peng Yan, PH.D., Founder and Consultant
Dr. Yan is currently President of Sai Yin Si, Inc., a biomedical consulting firm and is also Professor of Pharmaceutical Science at Guangxi Normal University in Guilin, China. She consults with the Company on various matters. Peng holds a Ph.D. in pharmaceutical science from Shanghai University.

 


Legal Advisors


Phoenix PharmaLabs is represented by:

 

 

Bruce W. Jenett, J.D., DLA Piper LLC, Corporate Counsel

Mr. Jenett is currently the Co-Chair for DLA Piper’s Global Life Sciences Practice, and he focuses on the representation of U.S. and international business and finance clients in the life sciences industry. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start- ups and large multinational corporations. Chambers USA: America's Leading Lawyers for Business, by the respected research publisher Chambers & Partners, consistently names Mr. Jenett one of the leading life sciences lawyers in the United States. Mr. Jenett received his J.D. from Georgetown University Law Center in 1976 and is licensed to practice in the states of California and New York.

 


James U. Jensen, J.D., M.B.A., Corporate Counsel - Utah Affairs 
Mr. Jensen is CEO of ClearWater Governance Group. He currently is of counsel to Woodbury & Kesler and serves as Chairman for Wasatch Funds, and Bayhill Capital Corporation (previously Cognigen Networks). He was a founder and served on the board of Intelisum, and he was a founder and served as CEO and director of Exeven Therapeutics Corp. He also serves on the board of directors of the University of Utah Research Foundation. Mr. Jensen holds JD and MBA degrees from Columbia University. 

 

 

Anne Maxwell, J.D. PH.D., Cantor Colburn LLP, Patent Counsel 

Dr. Maxwell is a Partner at Cantor Colburn specializing in the preparation and prosecution of patent applications for small molecule drugs, assays, and pharmaceutical formulations. Dr. Maxwell also is an expert manager of foreign prosecution, with extensive experience in coordinating worldwide prosecution for pharmaceutical patent applications. She was previously a Patent Agent and Post-Doctoral Fellow at Neurogen Corporation.Dr. She is a member of the American Bar Association, the Connecticut Bar Association, the New York Bar Association, and the American Intellectual Property Law Association. She is admitted to practice in Connecticut and New York, and is registered to practice before the United States Patent and Trademark Office. Anne received both BA and BS degrees from the University of Illinois, received a Ph.D. in Biophysical Chemistry from Yale University, and obtained a J.D. from the University of Connecticut School of Law.

 

 

 

 





News Flash

Phoenix PharmaLabs Releases New Data Confirming That Their Novel Opioid Shows No Signs of Addiction Potential

 

Phoenix PharmaLabs Releases New Data Confirming That Their <...
More details...


Novel Pinkiller with Little or No Signs of Addiction and Other Serious Opioid Side Effects Patented by Phoenix PharmaLabs

 

Novel Painkiller with Little or No Signs of Addiction and Other Serious Opioi...
More details...


Patent Awarded
"Use of PPL opiate in the treatment of opiate addiction." ...
More details...